-
Featured
Maximizing Clinical Utility of Pulmonary Optical Imaging
Massachusetts General Hospital researchers push the limits of pulmonary optical frequency domain imaging for in vivo diagnosis of lung cancer and assessment of asthmatic airways.
-
Capmatinib Benefits Adults with Advanced NSCLC and MET Exon 14 Skipping Mutation
Rebecca S. Heist, MD, MPH, and colleagues led the phase 2 GEOMETRY mono-1 trial, the basis for FDA approval of capmatinib, a highly specific new MET inhibitor for treatment of adults with MET exon 14–mutated metastatic non–small-cell lung cancer.
-
Some Physicians Knowingly Order Guideline-Discordant Lung Cancer Screening
Massachusetts General Hospital researchers found that for a small fraction of patients, lung cancer screening examinations were ordered knowingly outside of U.S. guidelines, including for never smokers, motivated in part by cancer risk perceptions.
-
Using Chest X-Rays, Artificial Intelligence Can Predict Risk of Lung Cancer
Massachusetts General Hospital researchers have reported a deep learning approach to identify high-risk smokers who should undergo lung cancer screening.
-
MET Alterations Are a Recurring Resistance Mechanism in ALK-Positive Lung Cancer
Massachusetts General Hospital Cancer Center researchers find that ALK/MET combination therapy is a rational approach to treatment of ALK-positive non-small-cell lung cancer.
-
Treating Lung Metastases with Image-Guided Ablation
Image-guided ablation represents an alternative approach for patients who cannot undergo surgery or radiation due to the extent of metastatic disease or comorbidities including limited respiratory function, advanced age or prior radiation therapy.
Lung Cancer Contributors
-
Aaron Hata, MD, PhD
Assistant Physician, Hematology and Oncology, Massachusetts General Hospital, Assistant Professor of Medicine, Harvard Medical School
Recent Article
MET Alterations Are a Recurring Resistance Mechanism in ALK-Positive Lung Cancer
-
Aaron L. Baggish, MD
Director, Cardiovascular Performance Program, Director, Cardiovascular Performance Program Fellowship
Recent Article
How COVID-19 Affects the Heart, Especially in Athletes
-
Gary X. Wang, MD, PhD
Diagnostic Radiologist, Department of Radiology, Massachusetts General Hospital
Recent Article
Some Physicians Knowingly Order Guideline-Discordant Lung Cancer Screening -
Melissa J. Suter, PhD
Associate Professor in Medicine, Harvard Medical School, Assistant in Biomedical Engineering, Massachusetts General Hospital
Recent Article
Maximizing Clinical Utility of Pulmonary Optical Imaging -
Michael T. Lu, MD, MPH
Director of Research, Cardiovascular Imaging Division, Co-Director, Cardiovascular Imaging Research Center, Massachusetts General Hospital, Assistant Professor of Radiology, Harvard Medical School
Recent Article
Artificial Intelligence Estimates Biological Age, Predicts Mortality From a Chest X-ray -
Rebecca Suk Heist, MD, MPH
Associate Professor of Medicine at Harvard Medical School, Physician in the Division of Hematology/Oncology, Mass General Cancer Center
Recent Article
Capmatinib Benefits Adults with Advanced NSCLC and MET Exon 14 Skipping Mutation
-
Udo Hoffmann, MD
Director, Cardiac MR PET CT Program, Mass General, Division Chief, Cardiovascular Imaging, Mass General, Professor of Radiology, HMS
Recent Article
Discordance Across High-Sensitivity Troponin Assays Can Affect Management of Suspected ACS
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
